News List

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion

European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke

Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September

Blueprint Medicines announced that the European Medicines Agency (EMA) Committee for Medicinal Produ

Gilead's Veklury has been approved:Veklury is the First Approved Treatment Option for COVID-19 in the European Union

At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04,

Announcement on the extension of CPHI North America 2020 in September

Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame

New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!

Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new

The first c-Met inhibitor approved by the FDA to market

On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien